Menu
Back to Journals » Hepatic Medicine: Evidence and Research
Hepatic Medicine: Evidence and Research
- View all (107)
- Volume 11, 2019 (5)
- Volume 10, 2018 (13)
- Volume 9, 2017 (10)
- Volume 8, 2016 (15)
- Volume 7, 2015 (8)
- Volume 6, 2014 (12)
- Volume 5, 2013 (7)
- Volume 4, 2012 (7)
- Volume 3, 2011 (14)
- Volume 2, 2010 (14)
- Volume 1, 2009 (2)
Journal Articles:
- 107 records -
Cognitive impairment after liver transplantation: residual hepatic encephalopathy or posttransplant encephalopathy?
Kornerup LS, Pflugrad H, Weissenborn K, Vilstrup H, Dam G
Hepatic Medicine: Evidence and Research 2019, 11:41-46
Published Date: 18 March 2019
Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection
Bernstein D, Tripathi R, Cohen DE
Hepatic Medicine: Evidence and Research 2019, 11:35-40
Published Date: 13 February 2019
Portosystemic shunts and refractory hepatic encephalopathy: patient selection and current options
Philips CA, Rajesh S, Augustine P, Padsalgi G, Ahamed R
Hepatic Medicine: Evidence and Research 2019, 11:23-34
Published Date: 25 January 2019
Spontaneous bacterial peritonitis in patients with cirrhosis: incidence, outcomes, and treatment strategies
Marciano S, Diaz JM, Dirchwolf M, Gadano A
Hepatic Medicine: Evidence and Research 2019, 11:13-22
Published Date: 14 January 2019
Practical steps to improve chronic hepatitis C treatment in people with opioid use disorder
Roncero C, Ryan P, Littlewood R, Macías J, Ruiz J, Seijo P, Palma-Alvarez RF, Vega P
Hepatic Medicine: Evidence and Research 2019, 11:1-11
Published Date: 24 December 2018
Comparison of extracorporeal cellular therapy (ELAD®) vs standard of care in a randomized controlled clinical trial in treating Chinese subjects with acute-on-chronic liver failure
Duan Z, Xin S, Zhang J, You S, Chen Y, Liu H, Zheng S, Li Z, Ashley R, Millis M
Hepatic Medicine: Evidence and Research 2018, 10:139-152
Published Date: 16 November 2018
Universal Index for Cirrhosis (UIC index): The development and validation of a novel index to predict advanced liver disease
Ahmed Z, Ren J, Gonzalez A, Ahmed U, Walayat S, Martin DK, Moole H, Yong S, Koppe S, Dhillon S
Hepatic Medicine: Evidence and Research 2018, 10:133-138
Published Date: 24 October 2018
Expert opinion on the management of hepatitis C infection in Kuwait
Saad MF, Alenezi S, Asker H
Hepatic Medicine: Evidence and Research 2018, 10:117-132
Published Date: 28 September 2018
Acute pediatric hyperammonemia: current diagnosis and management strategies
Savy N, Brossier D, Brunel-Guitton C, Ducharme-Crevier L, Du Pont-Thibodeau G, Jouvet P
Hepatic Medicine: Evidence and Research 2018, 10:105-115
Published Date: 12 September 2018
Progressive familial intrahepatic cholestasis: diagnosis, management, and treatment
Gunaydin M, Bozkurter Cil AT
Hepatic Medicine: Evidence and Research 2018, 10:95-104
Published Date: 10 September 2018
Copeptin as a novel marker predicting prognosis of liver cirrhosis and its major complications
Tawfik AK, Helmy A, Yousef M, Abou-Saif S, Kobtan A, Asaad E, Abd-Elsalam S
Hepatic Medicine: Evidence and Research 2018, 10:87-93
Published Date: 4 September 2018
Hepatitis C in Lebanon: the burden of the disease and the value of comprehensive screening and treatment
Abou Rached A, Abou Kheir S, Saba J, Assaf S, Kassis G, Sanchez Gonzalez Y, Ethgen O
Hepatic Medicine: Evidence and Research 2018, 10:73-85
Published Date: 28 August 2018
Management of refractory cirrhotic ascites: challenges and solutions
Fukui H, Kawaratani H, Kaji K, Takaya H, Yoshiji H
Hepatic Medicine: Evidence and Research 2018, 10:55-71
Published Date: 3 July 2018
Biomarkers for primary biliary cholangitis: current perspectives
Kouroumalis E, Samonakis D, Voumvouraki A
Hepatic Medicine: Evidence and Research 2018, 10:43-53
Published Date: 18 June 2018
Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy
Sulejmani N, Jafri SM
Hepatic Medicine: Evidence and Research 2018, 10:33-42
Published Date: 4 May 2018
Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial
Alam S, Ghosh J, Mustafa G, Kamal M, Ahmad N
Hepatic Medicine: Evidence and Research 2018, 10:23-31
Published Date: 27 April 2018
Diagnosis and staging of fibrosis in patients with chronic hepatitis C: comparison and critical overview of current strategies
Mendes LC, Stucchi RSB, Vigani AG
Hepatic Medicine: Evidence and Research 2018, 10:13-22
Published Date: 3 April 2018
Hepatic encephalopathy: current challenges and future prospects
Swaminathan M, Ellul MA, Cross TJS
Hepatic Medicine: Evidence and Research 2018, 10:1-11
Published Date: 22 March 2018
Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort
Kutala BK, Mouri F, Castelnau C, Bouton V, Giuily N, Boyer N, Asselah T, Marcellin P
Hepatic Medicine: Evidence and Research 2017, 9:67-73
Published Date: 18 December 2017
PNPLA3 expression and its impact on the liver: current perspectives
Bruschi FV, Tardelli M, Claudel T, Trauner M
Hepatic Medicine: Evidence and Research 2017, 9:55-66
Published Date: 6 November 2017
Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement
Tag-Adeen M, Sabra AM, Akazawa Y, Ohnita K, Nakao K
Hepatic Medicine: Evidence and Research 2017, 9:45-53
Published Date: 6 October 2017
Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy
Roggeri DP, Roggeri A
Hepatic Medicine: Evidence and Research 2017, 9:37-43
Published Date: 25 September 2017
Hepatitis C infection in Egypt: prevalence, impact and management strategies [Corrigendum]
Gomaa A, Allam N, Elsharkawy A, El Kassas M, Waked I
Hepatic Medicine: Evidence and Research 2017, 9:35-36
Published Date: 26 July 2017
Role of intrafamilial transmission in high prevalence of hepatitis C virus in Egypt
Omar MZ, Metwally MA, El-Feky HM, Ahmed IA, Ismail MA, Idris A
Hepatic Medicine: Evidence and Research 2017, 9:27-33
Published Date: 14 June 2017
Hepatitis C infection in Egypt: prevalence, impact and management strategies
Gomaa A, Allam N, Elsharkawy A, El Kassas M, Waked I
Hepatic Medicine: Evidence and Research 2017, 9:17-25
Published Date: 15 May 2017
Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C
Naylor PH, Mutchnick M
Hepatic Medicine: Evidence and Research 2017, 9:13-16
Published Date: 16 March 2017
Interrelationship of hepatitis C virus genotypes with patient characteristics in Bahrain
Abdulla MA, Murad EA, Aljenaidi HA, Aljowder DR, Aljeeran OIK, Farid E, Al Qamish JR
Hepatic Medicine: Evidence and Research 2017, 9:7-11
Published Date: 1 March 2017
Unresectable hepatoblastoma: current perspectives
Trobaugh-Lotrario AD, Meyers RL, O'Neill AF, Feusner JH
Hepatic Medicine: Evidence and Research 2017, 9:1-6
Published Date: 1 February 2017
Knowledge and attitude of health care professionals regarding hepatitis B virus infection and its vaccination, University of Gondar Hospital, Ethiopia
Ayalew MB, Horssa BA, Getachew N, Amare S, Getnet A
Hepatic Medicine: Evidence and Research 2016, 8:135-142
Published Date: 13 December 2016
Targeted transplantation of mitochondria to hepatocytes
Gupta N, Wu CH, Wu GY
Hepatic Medicine: Evidence and Research 2016, 8:115-134
Published Date: 29 November 2016
Defibrotide in the treatment of hepatic veno-occlusive disease
Fulgenzi A, Ferrero ME
Hepatic Medicine: Evidence and Research 2016, 8:105-113
Published Date: 31 October 2016
Presence and consequence of tooth periapical radiolucency in patients with cirrhosis
Grønkjær LL, Holmstrup P, Schou S, Schwartz K, Kongstad J, Jepsen P, Vilstrup H
Hepatic Medicine: Evidence and Research 2016, 8:97-103
Published Date: 13 September 2016
Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection
Bowlus CL
Hepatic Medicine: Evidence and Research 2016, 8:89-95
Published Date: 1 September 2016
Idiopathic noncirrhotic portal hypertension: current perspectives
Riggio O, Gioia S, Pentassuglio I, Nicoletti V, Valente M, d’Amati G
Hepatic Medicine: Evidence and Research 2016, 8:81-88
Published Date: 27 July 2016
Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
Sundaram V, Kowdley KV
Hepatic Medicine: Evidence and Research 2016, 8:75-80
Published Date: 28 June 2016
Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma
Baur J, Ritter CO, Germer CT, Klein I, Kickuth R, Steger U
Hepatic Medicine: Evidence and Research 2016, 8:69-74
Published Date: 20 June 2016
Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review
Hussaini T
Hepatic Medicine: Evidence and Research 2016, 8:61-68
Published Date: 18 May 2016
Hepatitis C in the Russian Federation: challenges and future directions
Mukomolov S, Trifonova G, Levakova I, Bolsun D, Krivanogova E
Hepatic Medicine: Evidence and Research 2016, 8:51-60
Published Date: 5 May 2016
The pathophysiology of thrombocytopenia in chronic liver disease
Mitchell O, Feldman DM, Diakow M, Sigal SH
Hepatic Medicine: Evidence and Research 2016, 8:39-50
Published Date: 15 April 2016
Autophagy: a new target for nonalcoholic fatty liver disease therapy
Mao YQ, Yu FJ, Wang JB, Guo CY, Fan XM
Hepatic Medicine: Evidence and Research 2016, 8:27-37
Published Date: 24 March 2016
Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
Pol S, Corouge M, Vallet-Pichard A
Hepatic Medicine: Evidence and Research 2016, 8:21-26
Published Date: 4 March 2016
Autophagy in hepatocellular carcinomas: from pathophysiology to therapeutic response
Dash S, Chava S, Chandra PK, Aydin Y, Balart LA, Wu T
Hepatic Medicine: Evidence and Research 2016, 8:9-20
Published Date: 22 February 2016
Challenging hepatitis C-infected liver transplant patients
Oliver M, Chiodo Ortiz C, Ortiz J
Hepatic Medicine: Evidence and Research 2016, 8:1-8
Published Date: 18 January 2016
Association of cytokine gene polymorphisms with hepatitis C virus infection in a population from Rio de Janeiro, Brazil
Fabrício-Silva GM, Poschetzky BS, Perez RM, Santos RC, Cavalini LT, Porto LC
Hepatic Medicine: Evidence and Research 2015, 7:71-79
Published Date: 2 November 2015
Interferon-free combination therapies for the treatment of hepatitis C: current insights
Holmes JA, Thompson AJ
Hepatic Medicine: Evidence and Research 2015, 7:51-70
Published Date: 2 November 2015
Management options in decompensated cirrhosis
Shah NL, Banaei YP, Hojnowski KL, Cornella SL
Hepatic Medicine: Evidence and Research 2015, 7:43-50
Published Date: 15 July 2015
Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs
Roggeri DP, Roggeri A, Rossi E, Cinconze E, Gasbarrini A, Monici Preti P, De Rosa M
Hepatic Medicine: Evidence and Research 2015, 7:37-42
Published Date: 13 July 2015
Tyrosine levels are associated with insulin resistance in patients with nonalcoholic fatty liver disease
Kawanaka M, Nishino K, Oka T, Urata N, Nakamura J, Suehiro M, Kawamoto H, Chiba Y, Yamada G
Hepatic Medicine: Evidence and Research 2015, 7:29-35
Published Date: 3 June 2015
Percutaneous hepatic radiofrequency for hepatocellular carcinoma: results and outcome of 46 patients
Bertrand J, Caillol F, Borentain P, Raoul JL, Heyries L, Bories E, Pesenti C, Ratone JP, Bernard JP, Gerolami R, Giovannini M
Hepatic Medicine: Evidence and Research 2015, 7:21-27
Published Date: 19 May 2015
Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?
Janardhan SV, Reau NS
Hepatic Medicine: Evidence and Research 2015, 7:11-20
Published Date: 16 April 2015
Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility
Ferrín G, Aguilar-Melero P, Rodríguez-Perálvarez M, Montero-Álvarez JL, de la Mata M
Hepatic Medicine: Evidence and Research 2015, 7:1-10
Published Date: 13 April 2015
Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?
Lim TR
Hepatic Medicine: Evidence and Research 2014, 6:113-118
Published Date: 3 December 2014
Surgical treatment of nonalcoholic fatty liver disease in severely obese patients
Vander Naalt SJ, Gurria JP, Holterman AXL
Hepatic Medicine: Evidence and Research 2014, 6:103-112
Published Date: 29 October 2014
Systemic vascular resistance in cirrhosis: a predictor of severity?
Gaduputi V, Abdulsamad M, Sakam S, Abbas N, Tariq H, Ihimoyan A
Hepatic Medicine: Evidence and Research 2014, 6:95-101
Published Date: 6 August 2014
Transarterial chemoembolization using iodized oil for unresectable hepatocellular carcinoma: perspective from multistep hepatocarcinogenesis
Yoshimitsu K
Hepatic Medicine: Evidence and Research 2014, 6:89-94
Published Date: 3 July 2014
Ending hepatitis C in the United States: the role of screening
Coffin PO, Reynolds A
Hepatic Medicine: Evidence and Research 2014, 6:79-87
Published Date: 3 July 2014
Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
Kamal SM
Hepatic Medicine: Evidence and Research 2014, 6:61-77
Published Date: 24 June 2014
Transmission, diagnosis, and management of hepatitis E: an update
Mirazo S, Ramos N, Mainardi V, Gerona S, Arbiza J
Hepatic Medicine: Evidence and Research 2014, 6:45-59
Published Date: 3 June 2014
Hepatitis C in Argentina: epidemiology and treatment
Gaite LA, Marciano S, Galdame OA, Gadano AC
Hepatic Medicine: Evidence and Research 2014, 6:35-43
Published Date: 27 May 2014
Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives
Degasperi E, Aghemo A
Hepatic Medicine: Evidence and Research 2014, 6:25-33
Published Date: 29 April 2014
A lipid-rich gestational diet predisposes offspring to nonalcoholic fatty liver disease: a potential sequence of events
Hughes AN, Oxford JT
Hepatic Medicine: Evidence and Research 2014, 6:15-23
Published Date: 6 March 2014
New-onset ascites as a manifestation of virologic relapse in patients with hepatitis C cirrhosis
Chua DL, Hahambis T, Sigal SH
Hepatic Medicine: Evidence and Research 2014, 6:11-14
Published Date: 29 January 2014
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease
Bradford V, Dillon JF, Miller MH
Hepatic Medicine: Evidence and Research 2014, 6:1-10
Published Date: 11 December 2013
A case of hepatic portal venous gas due to viral gastroenteritis
Mirmanesh M, Nguyen QS, Markelov A
Hepatic Medicine: Evidence and Research 2013, 5:63-65
Published Date: 21 October 2013
Novel drugs in the management of difficult-to-treat hepatitis C genotypes
Cartwright EJ, Miller L
Hepatic Medicine: Evidence and Research 2013, 5:53-61
Published Date: 20 August 2013
Direct comparison of the FibroScan XL and M probes for assessment of liver fibrosis in obese and nonobese patients
Durango E, Dietrich C, Seitz HK, Kunz CU, Pomier-Layrargues GT, Duarte-Rojo A, Beaton M, Elkhashab M, Myers RP, Mueller S
Hepatic Medicine: Evidence and Research 2013, 5:43-52
Published Date: 4 July 2013
The right choice of antihypertensives protects primary human hepatocytes from ethanol- and recombinant human TGF-β1-induced cellular damage
Ehnert S, Lukoschek T, Bachmann A, Martinez Sanchez JJ, Damm G, Nussler NC, Pscherer S, Stöckle U, Dooley S, Mueller S, Nussler AK
Hepatic Medicine: Evidence and Research 2013, 5:31-41
Published Date: 22 March 2013
The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia
Danish FA, Yasmin S
Hepatic Medicine: Evidence and Research 2013, 5:17-30
Published Date: 15 March 2013
Treatment of nonalcoholic steatohepatitis with vitamins E and C: a pilot study
Kawanaka M, Nishino K, Nakamura J, Suehiro M, Goto D, Urata N, Oka T, Kawamoto H, Nakamura H, Yodoi J, Hino K, Yamada G
Hepatic Medicine: Evidence and Research 2013, 5:11-16
Published Date: 4 March 2013
Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine
Lau T, Ahmad J
Hepatic Medicine: Evidence and Research 2013, 5:1-10
Published Date: 11 February 2013
Natural history and management of primary biliary cirrhosis
Al-Harthy N, Kumagi T
Hepatic Medicine: Evidence and Research 2012, 4:61-71
Published Date: 4 December 2012
Persistence of immunity from 1 year of age after one or two doses of hepatitis A vaccine given to children in Argentina
Espul C, Benedetti L, Cuello H, Houillon G, Rasuli A
Hepatic Medicine: Evidence and Research 2012, 4:53-60
Published Date: 28 August 2012
Acute hepatic failure in pediatric H1N1 infection: a case report from Al-Adan Hospital, Kuwait
Al-Refaee F
Hepatic Medicine: Evidence and Research 2012, 4:49-51
Published Date: 18 July 2012
Update on entecavir in the management of severe forms of Hepatitis B
Sacco R
Hepatic Medicine: Evidence and Research 2012, 4:39-47
Published Date: 15 May 2012
Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics
Dhanasekaran R, Limaye A, Cabrera R
Hepatic Medicine: Evidence and Research 2012, 4:19-37
Published Date: 8 May 2012
Transient elastography with the XL probe rapidly identifies patients with nonhepatic ascites
Kohlhaas A, Durango E, Millonig G, Bastard C, Sandrin L, Golriz M, Mehrabi A, Büchler MW, Seitz HK, Mueller S
Hepatic Medicine: Evidence and Research 2012, 4:11-18
Published Date: 1 May 2012
Epidemiology and treatment of autoimmune hepatitis
Francque S, Vonghia L, Ramon A, Michielsen P
Hepatic Medicine: Evidence and Research 2012, 4:1-10
Published Date: 16 March 2012
Rifaximin in the treatment of hepatic encephalopathy
Iadevaia MD, Del Prete A, Cesaro C, Gaeta L, Zulli C, Loguercio C
Hepatic Medicine: Evidence and Research 2011, 3:109-117
Published Date: 22 December 2011
A newborn liver mass that never existed: a somber reminder of embryonic ties between umbilical vein and portal venous system
Haafiz A, Williams JL, Andres JM, Novak DA
Hepatic Medicine: Evidence and Research 2011, 3:107-108
Published Date: 14 December 2011
Decline in HAV-associated fulminant hepatic failure and liver transplant in children in Argentina after the introduction of a universal hepatitis A vaccination program
Cervio G, Trentadue J, D´Agostino DE, Luque C, Giorgi MA, Armoni J, Debbag R
Hepatic Medicine: Evidence and Research 2011, 3:99-106
Published Date: 19 September 2011
Inhibition of Notch signaling affects hepatic oval cell response in rat model of 2AAF-PH
Darwiche H, Oh S-H, Steiger-Luther NC, Williams JM, Pintilie DG, Shupe TD, Petersen BE
Hepatic Medicine: Evidence and Research 2011, 3:89-98
Published Date: 5 September 2011
Autonomic dysfunction in chronic liver disease
Frith J, Newton JL
Hepatic Medicine: Evidence and Research 2011, 3:81-87
Published Date: 23 August 2011
Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies
Ismail MH, Pinzani M
Hepatic Medicine: Evidence and Research 2011, 3:69-80
Published Date: 4 July 2011
Selected biochemical and hematological abnormalities in Nigerians with human immunodeficiency virus and hepatitis C virus coinfection
Obienu O, Nwokediuko SC
Hepatic Medicine: Evidence and Research 2011, 3:63-68
Published Date: 30 June 2011
Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients
Locke JE, Singer AL
Hepatic Medicine: Evidence and Research 2011, 3:53-62
Published Date: 13 May 2011
Type I interferon receptor in peripheral blood mononuclear cells may predict response to intra-arterial 5-fluorouracil + interferon therapy for advanced hepatocellular carcinoma
Tomiyama Y, Yoshioka N, Yanai Y, Kawase T, Nishina S, Hara Y, Yoshida K, Korenaga K, Korenaga M, Hino K
Hepatic Medicine: Evidence and Research 2011, 3:45-52
Published Date: 26 April 2011
Scavenger receptor class B member 1 protein: hepatic regulation and its effects on lipids, reverse cholesterol transport, and atherosclerosis
Kent AP, Stylianou IM
Hepatic Medicine: Evidence and Research 2011, 3:29-44
Published Date: 8 April 2011
Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus
Bruno S, Savojardo D, Almasio PL, Mondelli MU
Hepatic Medicine: Evidence and Research 2011, 3:21-28
Published Date: 30 March 2011
Erratum
Xiao N, Shi S, Zhuang H
Hepatic Medicine: Evidence and Research 2011, 3:19-20
Published Date: 18 March 2011
Serum anti-modified citrullinated vimentin antibody concentration is associated with liver fibrosis in patients with chronic hepatitis
Suad Abdeen, Samuel O Olusi, Sunila George
Hepatic Medicine: Evidence and Research 2011, 3:13-18
Published Date: 10 March 2011
Pathogenesis and management of alcoholic liver cirrhosis: a review
Yi-Wen Huang, Sien-Sing Yang, Jia-Horng Kao
Hepatic Medicine: Evidence and Research 2011, 3:1-11
Published Date: 24 December 2010
Update on new approaches in the management of hepatocellular carcinoma
Giuseppe Cabibbo, Michela Antonucci, Chiara Genco
Hepatic Medicine: Evidence and Research 2010, 2:163-172
Published Date: 26 November 2010
Relationship between serum HBsAg level, HBV DNA level, and peripheral immune cells in patients with chronic hepatitis B virus infection
RM Mukherjee, P Balkumar Reddy, Jyothi Arava, et al
Hepatic Medicine: Evidence and Research 2010, 2:157-162
Published Date: 16 November 2010
Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma
Jen-Jung Pan, Milind Javle, Mie Mie Thinn, et al
Hepatic Medicine: Evidence and Research 2010, 2:147-155
Published Date: 2 November 2010
Potential treatment options and future research to increase hepatitis C virus treatment response rate
Veronica TenCate, Bruno Sainz Jr, Scott J Cotler, et al
Hepatic Medicine: Evidence and Research 2010, 2:125-145
Published Date: 1 October 2010
Morphological and functional MDCT: problem-solving tool and surrogate biomarker for hepatic disease clinical care and drug discovery in the era of personalized medicine
Liang Wang
Hepatic Medicine: Evidence and Research 2010, 2:111-124
Published Date: 17 August 2010
A meta-analysis that compares the use of either peginterferon-α2a or peginterferon-α2b plus ribavirin for HCV infection
Nan Xiao, Shuang Shi, Hui Zhuang
Hepatic Medicine: Evidence and Research 2010, 2:99-109
Published Date: 28 July 2010
Optimal management of hepatorenal syndrome in patients with cirrhosis
Paolo Angeli, Filippo Morando
Hepatic Medicine: Evidence and Research 2010, 2:87-98
Published Date: 21 June 2010
Anti-inflammatory action of insulin via induction of Gadd45-β transcription by the mTOR signaling pathway
Katherine D Bortoff, Adam B Keeton, J Lee Franklin, et al
Hepatic Medicine: Evidence and Research 2010, 2:79-85
Published Date: 24 June 2010
Mice with null mutation of Ceacam1 develop nonalcoholic steatohepatitis
Sumona Ghosh, Meenakshi Kaw, Payal R Patel, et al
Hepatic Medicine: Evidence and Research 2010, 2:69-78
Published Date: 31 May 2010
Liver stiffness: a novel parameter for the diagnosis of liver disease
Sebastian Mueller, Laurent Sandrin
Hepatic Medicine: Evidence and Research 2010, 2:49-67
Published Date: 25 May 2010
Hypothesis: Targeted Ikkβ deletion upregulates MIF signaling responsiveness and MHC class II expression in mouse hepatocytes
Katherine S Koch, Hyam L Leffert
Hepatic Medicine: Evidence and Research 2010, 2:39-47
Published Date: 23 March 2010
Mechanism of the inhibitory effect of ghrelin in sepsis
Asha Jacob, Rongqian Wu, Mian Zhou, et al
Hepatic Medicine: Evidence and Research 2010, 2:33-38
Published Date: 23 February 2010
Insulin-like growth factor binding protein-3 is required for the regulation of rat oval cell proliferation and differentiation in the 2AAF/PHX model
Nicole C Steiger-Luther, Houda Darwiche, Seh-Hoon Oh, et al
Hepatic Medicine: Evidence and Research 2010, 2:13-32
Published Date: 3 February 2010
Cyclic AMP-guanine exchange factor activation inhibits JNK-dependent lipopolysaccharide-induced apoptosis in rat hepatocytes
Kathleen Ponzetti, Melissa King, Anna Gates, et al
Hepatic Medicine: Evidence and Research 2010, 2:1-11
Published Date: 11 January 2010
Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors
M Gabrovska, F Geurs, S Ponette, et al
Hepatic Medicine: Evidence and Research 2009, 1:9-12
Published Date: 30 October 2009
A high prevalence of extreme hyperferritinemia in acute hepatitis patients
Kazuhiro Kotoh, Akihiro Ueda, Masatake Tanaka, et al.
Hepatic Medicine: Evidence and Research 2009, 1:1-7
Published Date: 14 September 2009